論文（英文）

• Fujita S, Cencini M, Buonincontri G, Takei N, Schulte RF, Fukunaga I, Uchida W, Hagiwara A, Kamagata K, Hagiwara Y, Matsuyama Y, Abe O, Tosetti M, Aoki S. Simultaneous Relaxometry and Morphometry of Human Brain Structures with Three-dimensional Magnetic Resonance Fingerprinting: A Multicenter, Multiplatform, Multi-field-strength Study. Cereb Cortex. 2022. doi: 10.1093/cercor/bhab259. Online ahead of print.
• Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M. Cost-effectiveness of trastuzumab with or without chemotherapy as adjuvant therapy in HER2-positive elderly breast cancer patients: a randomized, open-label clinical trial, the RESPECT trial. Clin Drug Investig. 2022. doi: 10.1007/s40261-022-01124-y. Online ahead of print.
• Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Yoshihide A, Yoshizaki A, Sato S. Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4364-4373. doi: 10.1093/rheumatology/keac023.
• Ishigami H, Tsuji Y, Shinohara H, Kodera Y, Kanda M, Yabusaki H, Ito S, Imano M, Yamashita H, Hidemura A, Yamaguchi H, Fukagawa T, Oba K, Kitayama J, Seto Y. Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. J Clin Med. 2021 Nov 30;10(23):5666. doi: 10.3390/jcm10235666.
• Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. Diagnostics (Basel). 2021 Dec 4;11(12):2274. doi: 10.3390/diagnostics11122274.
• Murasato Y, Watanabe Y, Yamawaki M, Kinoshita Y, Okubo M, Yumoto K, Masuda N, Otake H, Aoki J, Nakazawa G, Numasawa Y, Ito T, Shite J, Okamura T, Takagi K, Kozuma K, Lefèvre T, Chevalier B, Louvard Y, Suzuki N, Kozuma K; PROPOT investigators. Effect of proximal optimization technique on coronary bifurcation stent failure: Insights from the multicenter randomized PROPOT trial. Catheter Cardiovasc Interv. 2022 Feb 16. doi: 10.1002/ccd.30120. Online ahead of print.
• Hagiwara Y, Shiroiwa T. Estimating Value-Based Price and Quantifying Uncertainty Around It in Health Technology Assessment: Frequentist and Bayesian Approaches. Med Decis Making. 2022 Feb 17. doi: 10.1177/0272989X221079554. Online ahead of print.
• Matsumoto H, Igarashi A, Hagiwara Y, Yamamoto-Mitani N. Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers. Contemp Clin Trials Commun. 2022;26:100896.
• Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg. 2021;S0278-2391(21)01511-1. doi: 10.1016/j.joms.2021.12.007. Online ahead of print.
• Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial. Qual Life Res. 2022 Jan 4. doi: 10.1007/s11136-021-03074-y. Online ahead of print.
• Fuyama K, Hagiwara Y, Matsuyama Y. A simulation study of regression approaches for estimating risk ratios in the presence of multiple confounders. Emerg Themes Epidemiol. 2021;18:18.
• Ito C, Hashimoto A, Uemura K, Oba K. Misleading Reporting (Spin) in Noninferiority Randomized Clinical Trials in Oncology With Statistically Not Significant Results: A Systematic Review. JAMA Netw Open. 2021 Dec 1;4(12):e2135765. doi: 10.1001/jamanetworkopen.2021.35765.
• Miyo M, Kato T, Nakamura Y, Taniguchi H, Takahashi Y, Ishii M, Okita K, Ando K, Yukami H, Mishima S, Yamazaki K, Kotaka M, Watanabe J, Oba K, Aleshin A, Billings PR, Rabinowitz M, Kotani D, Oki E, Takemasa I, Mori M, Yoshino T. DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Sci. 2022 Apr;113(4):1531-1534. doi: 10.1111/cas.15226.
• Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Kishikawa J, Ishii H, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Oba K, Ishihara S. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study. Int J Clin Oncol. 2022 Jan;27(1):141-153. doi: 10.1007/s10147-021-02062-z.
• Machida H, Matsuo K, Oba K, Aoki D, Enomoto T, Okamoto A, Katabuchi H, Nagase S, Mandai M, Yaegashi N, Yamagami W, Mikami M. Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. J Gynecol Oncol. 2022 Jan;33(1):e3. doi: 10.3802/jgo.2022.33.e3.
• Hojo D, Murono K, Nozawa H, Kawai K, Hata K, Tanaka T, Oba K, Ishihara S. Improvement in Surgical Outcomes Using 3D Printed Models for Lateral Pelvic Lymph Node Dissection in Rectal Cancer. Dis Colon Rectum. 2022 Apr 1;65(4):566-573. doi: 10.1097/DCR.0000000000002327.
• Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol. 2022 Jan;49(1):179-183. doi: 10.1111/1346-8138.16206.
• Ota K, Oba K, Ito Y, Cheng J, Ota K, Takasu A. Focused Assessment with Sonography for Trauma (FAST) training for first-year resident physicians at a university hospital in Japan: A longitudinal, observational study. SAGE Open Medicine. 2021;9: 20503121211044367.
• Furihata R, Kuwabara M, Oba K, Watanabe K, Takano N, Nagamine N, Maruyama Y, Ito N, Watanabe I, Tsubono K, Ikeda C, Sakamoto J. Association between working overtime and psychological stress reactions in elementary and junior high school teachers in Japan: A large-scale cross-sectional study. Ind Health. 2022 Apr 1;60(2):133-145.
• Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, Murakami T, Kudo M, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S. Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. Hepatol Res. 2021; 51(8): 890-901.
• Kokudo T, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Ishihara S, Makuuchi M, Kokudo N, Hasegawa K. Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases. Surgery. 2021; 170(4): 1151-1154.
• Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res. 2021; 51(4): 355-405.
• Nii M, Inuzuka R, Inai K, Shimada E, Shinohara T, Kogiso T, Ono H, Ootsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukochi S, Yoshikawa T, Furutani Y, Shinozaki T, Matsuyama Y, Senzaki H, Tokushige K, Nakanishi T. Incidence and expected probability of liver cirrhosis and hepatocellular carcinoma after fontan pperation. Circulation. 2021; 144(25): 2043-2045.
• Yamamuro S, Shinozaki T, Imuro S, Matsuyama Y. Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin’s effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Statistical Methods in Medical Research 2021; 30(8): 1782-1799.
• Aramaki O, Takayama T, Moriguch I M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M; ACE 500 study group. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. European Journal of Cancer 2021; 157: 373-382.
• Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M. Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. World Journal of Surgery 2021; 45(2): 607-614.
• Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021; 56(3): 261-273.
• Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol. 2022 Feb;269(2):885-896. doi: 10.1007/s00415-021-10670-y.
• Iwagami M, Takeuchi Y. Introduction to self-controlled study design. Ann Clin Epidemiol. 2021; 3(3): 67-73.
• Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Non-parametric approach for frequentist multiple imputation in survival analysis with missing covariates. Stat Methods Med Res. 2021; 30(7): 1691-1707.
• Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Res Treat. 2021. https://doi.org/10.1007/s10549-021-06253-0
• Tani A, Saegusa Y, Ogawa K, Tomiyasu H, Takeuchi Y, Harada K, Kobayashi T, Setoguchi A, Nakamichi J, Mizuno T, Irie M, Tokita M, Fujita K, Suenaga M, Motegi T, Ohmi A, Goto-Koshino Y, Ohno K, Tsujimoto H. Construction and validation of a scoring system to predict resistance to chemotherapeutic drugs using gene expression profiles in canine lymphoma. Res Vet Sci. 2021; 137: 208-216.
• Watanabe Y, Murasato Y, Yamawaki M, Kinoshita Y, Okubo M, Yumoto K, Masuda N, Otake H, Aoki J, Nakazawa G, Numasawa Y, Ito T, Shite J, Okamura T, Takagi K, Kozuma K, Lefèvre T, Chevalier B, Louvard Y, Suzuki N, Kozuma K. Proximal Optimisation Technique Versus Final Kissing Balloon Inflation in Coronary Bifurcation Lesions: the Randomised, Multicenter PROPOT Trial. EuroIntervention. 2021. doi: 10.4244/EIJ-D-20-01386. Online ahead of print.
• Chamseddine AN, Oba K, Buyse M, Boku N, Bouché O, Satar T, Auperin A, Paoletti X. Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. Contemp Clin Trials. 2021 Jun:105:106400. doi: 10.1016/j.cct.2021.106400.
• Kato T, Kagawa Y, Kuboki Y, Gamoh M, Komatsu Y, Yasui H, Satake H, Oki E, Tanioka H, Kotaka M, Makiyama A, Denda T, Goto M, Yoshino T, Yamazaki K, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. Int J Clin Oncol. 2021 Jul;26(7):1238-1247. doi: 10.1007/s10147-021-01902-2.
• Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized controlled trial of paper-based at a hospital versus continual electronic patient-Reported outcomes at home for metastatic cancer patients: does electronic measurement at home detect patients' health status in greater detail? Med Decis Making. 2021. doi:10.1177/0272989X211010171.
• Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. Am J Gastroenterol. 2021. doi: 10.14309/ajg.0000000000001256.

TOP